MediWound Ltd. Banner Image

MediWound Ltd.

  • Ticker MDWD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
MediWound Ltd. Logo Image
  • 51-200 Employees
  • Based in Yavne, Israel
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®, non-surgically and rapidly removes burn escharMore without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
4.8 / 5.0 (110)

MediWound Ltd. reports have an aggregate usefulness score of 4.8 based on 110 reviews.

MediWound Ltd.

Most Recent Annual Report

MediWound Ltd.
MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

MediWound Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!